Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention
about
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic diseasePersistent platelet activation in patients with type 2 diabetes treated with low doses of aspirinA genome-wide association search for type 2 diabetes genes in African AmericansState-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.Diabetes is a proinflammatory state: a translational perspective.Acute suppression of circulating sCD40L during hyperglycemia and euglycemic-hyperinsulinemia in healthy young males.Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammationTicagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.Vascular effects of ultrafine particles in persons with type 2 diabetesThe fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix studyNative platelet aggregation and response to aspirin in persons with the metabolic syndrome and its componentsEmerging markers of atherosclerosis before and after bariatric surgeryPrevalence of aspirin resistance in diabetic patients and its associated factors.Anger is associated with increased IL-6 stress reactivity in women, but only among those low in social supportSoluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac CatheterizationHypertension in patients with type-II diabetes: relation to urinary albumin excretion, endothelial function and inflammation.Leukocyte Activation in Obese Patients: Effect of Bariatric Surgery.Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approachesRelationship between heart rate variability, interleukin-6, and soluble tissue factor in healthy subjects.Micro-RNA-126 Reduces the Blood Thrombogenicity in Diabetes Mellitus via Targeting of Tissue Factor.miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40Factors contributing to increased platelet reactivity in people with diabetesChanges of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Is the Mean Platelet Volume a Predictive Marker of a Low Apgar Score and Insulin Resistance in Gestational Diabetes Mellitus? A Retrospective Case-Control Study.Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.The CD40-CD40L system in cardiovascular disease.Silent brain infarction--a review of recent observations.Overcoming aspirin treatment failure in diabetes.Platelets, diabetes and myocardial ischemia/reperfusion injury.Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation.Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin.The association between impaired glucose tolerance and soluble CD40 ligand: a 15-year prospective cohort study.Tissue factor/factor VIIa signalling promotes cytokine-induced beta cell death and impairs glucose-stimulated insulin secretion from human pancreatic islets.Effect of resveratrol on platelet activation in hypercholesterolemic rats: CD40-CD40L system as a potential target.Pro-inflammatory biomakers in depression: treatment with venlafaxine.Response of blood platelets to beta-glucan from Saccharomyces cerevisiae.Antidiabetic Effect of Brain-Derived Neurotrophic Factor and Its Association with Inflammation in Type 2 Diabetes Mellitus.Soluble P-selectin levels in diabetes mellitus patients with coronary artery disease.Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: relationship to platelet volume, mass and granularity.
P2860
Q28218124-98417D41-48C7-46B8-BCC3-007614FCB15FQ28219419-661AE781-8A8F-4821-864D-C4FFF6E2E8BDQ28740367-985FDB62-B7CB-4B18-807B-8997CBD819D2Q30373414-D436DEEC-5728-433C-8614-334556AAFADDQ33693974-1F7D23B0-C740-4F29-BA02-3B83B434A4A0Q33768652-F9C889C9-3C61-4907-A10D-89BB5B4EB26DQ34018425-9B136E1D-1E80-4E2C-A413-73BFCF5B934AQ34404150-B685154A-DC09-4749-B2C2-5D5309515349Q34407458-C6AFD923-50E7-4C43-8146-FF1CE872C3DEQ35076036-F05A64C7-5D76-4691-B5DA-67E84B741478Q35104024-C685F76C-E85F-4751-AEAC-369CA42F1059Q35138237-6DCE995C-602A-405F-944E-A9458F0FC2EBQ35333201-BD20484A-7E02-4963-8C56-53B95F72FBCAQ35523918-6E99055C-AFEE-46DA-BEFD-2414B1078CC8Q35735264-0F3AC83E-4A7E-4A2E-A64C-72CBD7232179Q36091287-DF9626C6-264E-4E94-B901-B1F37AA53E30Q36195441-FCFB72AE-C172-4A50-B3FA-991A27BDE735Q36608474-2DC973C5-CBE8-4667-8355-8B03D17EDD34Q36639373-79DA5B9B-5777-4512-B08A-46CB287A92B8Q36973405-502AB358-9BA1-4FFE-AE2C-28FD2335C35EQ37093868-47AF84C8-0C04-40F5-BF4F-C271EFD53853Q37139534-1C424289-3AC2-4DD3-8881-60B6934C1B23Q37335279-FBCA67B2-83E6-4417-9D47-F6BD5C585683Q37435517-AAF28F15-5C19-4F87-AB09-0A153F2FA604Q37464600-577B119F-D745-4221-8E7D-0F3E68AD3D77Q37829738-2344094B-C7DE-4D56-9713-ECE5C98C05F4Q38032020-CB23CFC2-503F-4792-AE51-83A8CFCEC08FQ38055245-BB4AC167-BDFB-498D-B5BB-0EC93679C5AEQ39343342-5E7F106E-7B3F-48E7-88BC-BCE6DCAF8269Q40302136-017B84DD-0B24-4280-ADCF-2445DFEB0B67Q40693554-6003AEF5-DE3A-4BF4-A382-6427EEDEE8C8Q40988795-CA853026-E5E6-4C69-A86C-72676E57BCA8Q41553743-741B1D05-CE23-4DA3-B47B-05261B1CDBAEQ42740250-627E747B-98AE-4A0F-A34B-3B13F5416535Q43239654-B97185B8-210D-448A-A8E8-78A0F3D55565Q43248058-17C11CE1-4ECE-4F46-A62D-4F4F8FA7F9DDQ43373021-5659AF51-5FC7-46E1-9E1E-68EB6931AF37Q46231985-D9AFBD3E-25FA-4FAD-AB18-CCCCBF8C9472Q46372426-411DD988-480B-442B-BB82-7F0770F80BE7Q46845923-A1D124C3-FA26-46E7-9DB1-EF02C6FB46F1
P2860
Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Soluble CD40 ligand, soluble P ...... e and risk factor intervention
@ast
Soluble CD40 ligand, soluble P ...... e and risk factor intervention
@en
Soluble CD40 ligand, soluble P ...... e and risk factor intervention
@nl
type
label
Soluble CD40 ligand, soluble P ...... e and risk factor intervention
@ast
Soluble CD40 ligand, soluble P ...... e and risk factor intervention
@en
Soluble CD40 ligand, soluble P ...... e and risk factor intervention
@nl
prefLabel
Soluble CD40 ligand, soluble P ...... e and risk factor intervention
@ast
Soluble CD40 ligand, soluble P ...... e and risk factor intervention
@en
Soluble CD40 ligand, soluble P ...... e and risk factor intervention
@nl
P921
P3181
P1433
P1476
Soluble CD40 ligand, soluble P ...... e and risk factor intervention
@en
P2093
Andrew D Blann
Hoong Sern Lim
P304
P3181
P356
10.1161/01.CIR.0000129773.70647.94
P407
P577
2004-06-01T00:00:00Z